We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and ... Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. It employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older. Show more
Ask ADVFN Intelligence (AI)
CELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the...
CELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the...
CELEBRATION, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the...
MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense AmplifyAssist™, Zevra’s comprehensive patient support program...
FDA approval of MIPLYFFA™ and product launch cap third quarter filled with multiple commercial and clinical development milestones Zevra received rare pediatric disease Priority Review Voucher...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.69 | -7.84090909091 | 8.8 | 8.95 | 8.11 | 468552 | 8.42107633 | CS |
| 4 | -0.28 | -3.33730631704 | 8.39 | 8.95 | 8.1 | 540004 | 8.46231659 | CS |
| 12 | -0.4 | -4.70035252644 | 8.51 | 9.76 | 7.67 | 557403 | 8.69516254 | CS |
| 26 | 2.59 | 46.9202898551 | 5.52 | 9.76 | 5.45 | 843846 | 7.73810598 | CS |
| 52 | 1.96 | 31.8699186992 | 6.15 | 9.76 | 4.2 | 541519 | 7.2618618 | CS |
| 156 | 2.46 | 43.5398230088 | 5.65 | 9.76 | 3.89 | 398419 | 6.68817745 | CS |
| 260 | 2.46 | 43.5398230088 | 5.65 | 9.76 | 3.89 | 398419 | 6.68817745 | CS |
XMaster2023
3 minutes ago
RuudSaltis
4 minutes ago
XMaster2023
6 minutes ago
Whalatane
14 minutes ago
sab63090
24 minutes ago
sab63090
29 minutes ago
Bob Mullet
34 minutes ago
Guido2
35 minutes ago
Bob Mullet
38 minutes ago
Bob Mullet
38 minutes ago
MCArmel1
42 minutes ago
jeunke22
47 minutes ago
sab63090
48 minutes ago
Matt24777
51 minutes ago
Telling you there’s a chance
53 minutes ago
Tahoe2468
59 minutes ago
Lime Time
1 hour ago
skitahoe
1 hour ago
copytele
1 hour ago
chipboarder
1 hour ago
DesertDrifter
1 hour ago
joyceschoice
1 hour ago
dinogreeves
1 hour ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
